LABIANA HEALTH S.A.EO-10 (8RK) - Total Assets
Based on the latest financial reports, LABIANA HEALTH S.A.EO-10 (8RK) holds total assets worth €54.38 Million EUR (≈ $63.57 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 8RK operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
LABIANA HEALTH S.A.EO-10 - Total Assets Trend (2021–2024)
This chart illustrates how LABIANA HEALTH S.A.EO-10's total assets have evolved over time, based on quarterly financial data. See what is LABIANA HEALTH S.A.EO-10's book value for net asset value and shareholders' equity analysis.
LABIANA HEALTH S.A.EO-10 - Asset Composition Analysis
Current Asset Composition (December 2024)
LABIANA HEALTH S.A.EO-10's total assets of €54.38 Million consist of 55.2% current assets and 44.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €9.42 Million | 18.1% |
| Inventory | €9.98 Million | 19.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.03 Million | 11.6% |
| Goodwill | €-0.01 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how LABIANA HEALTH S.A.EO-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 8RK market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LABIANA HEALTH S.A.EO-10's current assets represent 55.2% of total assets in 2024, an increase from 43.0% in 2021.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, up from 4.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 17.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
LABIANA HEALTH S.A.EO-10 Competitors by Total Assets
Key competitors of LABIANA HEALTH S.A.EO-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
LABIANA HEALTH S.A.EO-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.32 | 1.32 |
| Quick Ratio | 0.86 | 0.80 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €9.19 Million | €6.89 Million | €6.89 Million |
LABIANA HEALTH S.A.EO-10 - Advanced Valuation Insights
This section examines the relationship between LABIANA HEALTH S.A.EO-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.89 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | -12.0% |
| Total Assets | €52.00 Million |
| Market Capitalization | $61.04 Million USD |
Valuation Analysis
Above Book Valuation: The market values LABIANA HEALTH S.A.EO-10's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: LABIANA HEALTH S.A.EO-10's assets decreased by 12.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LABIANA HEALTH S.A.EO-10 (2021–2024)
The table below shows the annual total assets of LABIANA HEALTH S.A.EO-10 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €52.00 Million ≈ $60.80 Million |
-12.05% |
| 2023-12-31 | €59.12 Million ≈ $69.12 Million |
-2.72% |
| 2022-12-31 | €60.78 Million ≈ $71.06 Million |
-11.10% |
| 2021-12-31 | €68.37 Million ≈ $79.93 Million |
-- |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more